OKUR Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
16.9M
+8.2%
15.6M
+10.5%
14.1M
-8.9%
15.5M
-5.0%
16.3M
R&D
12.6M
+7.7%
11.7M
+9.2%
10.7M
-10.0%
11.9M
-5.5%
12.6M
SG&A
4.3M
+9.7%
3.9M
+14.8%
3.4M
-5.0%
3.6M
-3.4%
3.7M
Operating Income
-16899000
-8.2%
-15615000
-10.5%
-14125000
+8.9%
-15501000
+5.0%
-16324000
EBITDA
-16812000
-8.4%
-15511000
-10.6%
-14021000
+8.9%
-15393000
+5.0%
-16207000
Net Income
-15346000
-1.2%
-15157000
-12.2%
-13503000
+8.1%
-14699000
+4.5%
-15390000
EPS (Basic)
$-0.31
+72.1%
$-1.11
-12.1%
$-0.99
+9.2%
$-1.09
+4.4%
$-1.14
EPS (Diluted)
$-0.31
+72.1%
$-1.11
-12.1%
$-0.99
+9.2%
$-1.09
+4.4%
$-1.14
Shares (Diluted)
49.9M
+264.7%
13.7M
+0.6%
13.6M
+0.5%
13.5M
+0.2%
13.5M
OnKure Therapeutics (OKUR) โ€” Financials